VolitionRx (NYSE:VNRX) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of VolitionRx (NYSE:VNRX) in a research report issued to clients and investors on Friday. The brokerage set a “sell” rating on the stock.

Separately, Benchmark reiterated a “hold” rating on shares of VolitionRx in a research report on Friday, August 16th.

VolitionRx Stock Performance

Shares of NYSE VNRX opened at $0.70 on Friday. The business has a 50-day moving average of $0.65 and a 200-day moving average of $0.69. The firm has a market capitalization of $64.47 million, a price-to-earnings ratio of -1.52 and a beta of 1.09. VolitionRx has a 12 month low of $0.43 and a 12 month high of $1.23.

VolitionRx (NYSE:VNRX) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01. The company had revenue of $0.40 million during the quarter, compared to the consensus estimate of $0.34 million. On average, analysts predict that VolitionRx will post -0.31 earnings per share for the current year.

Insider Activity

In related news, Director Guy Archibald Innes bought 150,000 shares of the stock in a transaction dated Tuesday, August 20th. The stock was bought at an average price of $0.67 per share, with a total value of $100,500.00. Following the purchase, the director now owns 406,683 shares in the company, valued at approximately $272,477.61. The trade was a 0.00 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 12.80% of the company’s stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.